Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: NOVARTIS
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A study to provide expanded access of Exjade deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with other locally approved iron chelators
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A retrospective pharmacogenetic analysis of patients with elevated liver enzymes (Hy s law cases or AST/ALT > 10x ULN) in clinical studies CCOX189A0117, CCOX189A2332, CCOX189A2369, CCOX189A0126, CCOX189A0112, CCOX189A0109 or CCOX189A2361
The primary objective of this post-hoc pharmacogenetic sub-study is to determine whether patients who experienced severe hepatotoxicity when taking lumiracoxib are carriers of the DQA1*0102 allele.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A randomized, open-label, controlled, multi-center two-year study comparing efficacy and safety of telbivudine LDT600 600 mg PO in combination with peg alpha-2a sq 180 g with peg alpha-2a monotherapy, and with telbivudine monotherapy in treatment na ve patients with HBeAg-positive compensated CHB
The primary objective of this study is to demonstrate the superior antiviral efficacy of the combination of peginterferon alpha-2a plus telbivudine vs. peginterferon alpha-2a monotherapy as demonstrat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS
Update Il y a 4 ans
Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)
The purpose of this study is to determine: (1) the safety and pharmacokinetics of APL180 administered as a single intravenous infusion in healthy volunteers, and (2) the safety, pharmacoki...
Country
Belgium
,
Denmark
,
Israel
,
Netherlands
,
South Africa
,
United Kingdom
,
United States
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
EVALUATION OF THE QUALITY OF LIFE AND GASTROINTESTINAL SYMPTOMS AFTER CONVERSION TO MYFORTIC (ERL080) and CELLCEPT WITHDRAWAL IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS TREATED WITH TACROLIMUS
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
An extension of a clinical study to investigate long term safety of tobramycin inhalation powder (TIP) in patients with Cystic Fibrosis Estensione di uno studio clinico per valutare la sicurezza a lungo termine di tobramicina polvere per inalazione (Tobramycin Inhalation Powder – TIP) in pazienti con fibrosi cistica
To assess the safety of Tobramycin Inhalation Powder (TIP) across 12 treatment cycles (6 treatment cycles in the core study and 6 treatment cycles in the extension study) in terms of the incidence...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A phase I/II open label, dose escalation trial to explore the safety and efficacy of ICL670 in patients with iron overload resulting from hereditary hemochromatosis
To explore the safety of ICL670 (dose range 5 to 20 mg/kg PO per day) in adult hemochromatosis patients homozygous for the C282Y mutation, with iron overload.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
An extension to a phase II open label study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis Estensione dello studio in aperto di fase II per determinare la tollerabilita` e l`efficacia antileucemica di STI571 in pazienti con leucemia mieloide cronica Ph+ in crisi blastica mieloide
To enable patients to have access to study drug and continue study treatment To decrease data collection to include only overall survival and serious adverse events Consentire ai pazienti ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonメs syndrome, non-functioning adenoma, TSH-adenoma, Gonadotroph adenoma, and PRL-adenoma) with potential sensitivity to somatostatin analogues
To evaluate the effect of SOM230 s.c. in patients with rare life threatening diseases as follows: Biochemical tumor markers for those patients with duodeno-pancreatic (neuro) endocrine tumors (insuli...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
NOVARTIS FARMA
Update Il y a 4 ans
A 24-weeks , national, multicenter, double blind controlled vs placebo trial to evaluate the efficacy of Neoral ciclosporine 5mg/kg/day , twice a week administered in reduction of the rate of relapse in pz with chronic plaque psoriasis on remission. PREWENT Study
Relapse rate during the 24-weeks treatment with Neoral ciclosporine 5mg/kg/day twice a week
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next